| Biomarker ID | 820 |
| PMID | 22126577 |
| Year | 2011 |
| Biomarker | Interleukin-10 (IL-10) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Increased expression in patients with poor survival |
| Odds Ratio/Hazard Ratio/Relative Risk | HR = 0.37 (95% CI: 0.18-0.69) |
| Effect on Pathways | Pathways Include:-Autoimmune thyroid disease,Leishmaniasis,Allograft rejection,Amoebiasis,SMAD2/3 nuclear pathway |
| Experiment | Survival Vs No Survival |
| Type of Biomarker | Prognostic |
| Cohort | Of a total of 149 patients, 71 had biopsy proven prostate cancers (TNM stage: T2=17, T3=26 and T4=28) and 78 clinical benign prostate hyperplasia (BPH).71 age matched controls were also selected |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | IL10 |